In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
By using an agar dilution method, the in vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, and five other agents were determined against 300 gram-positive and 54 gram-negative strains of intestinal anaerobes. Ramoplanin was active at <or=2 microg/ml against 287 of 300 (95.7%) gram-positive organisms, including 18 strains of Clostridium difficile for which MICs of ramoplanin were 0.25 to 0.5 microg/ml; for 3 of these, linezolid MICs were 8 to 16 micro g/ml. Nineteen Clostridium innocuum strains for which the vancomycin MIC at which 90% of strains were inhibited was 16 microg/ml were susceptible to ramoplanin at 0.06 to 0.25 microg/ml and to teicoplanin at 0.125 to 1.0 microg/ml. All strains of Eubacterium, Actinomyces, Propionibacterium, and Peptostreptococcus spp. were inhibited by <or=0.25 microg of ramoplanin per ml and <or=1 microg of vancomycin per ml. Ramoplanin was also active at <or=4 microg/ml against 15 of 22 of the Prevotella and Porphyromonas strains tested, but ramoplanin MICs for all 31 strains of the Bacteroides fragilis group, the Fusobacterium mortiferum-Fusobacterium varium group, and Veillonella spp. were >or=256 microg/ml. Ramoplanin displays excellent activity against C. difficile and other gram-positive enteric anaerobes, including vancomycin-resistant strains; however, it has poor activity against most gram-negative anaerobes and thus potentially has a lesser effect on the ecological balance of normal fecal flora.
Citron
D M
DM
R M Alden Research Laboratory, Santa Monica, California 90404, USA. d.m.citron@verizon.net
Merriam
C V
CV
Tyrrell
K L
KL
Warren
Y A
YA
Fernandez
H
H
Goldstein
E J C
EJ
D000081:Acetamides / Q000494:pharmacology; D000190:Actinomyces / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001414:Bacitracin / Q000494:pharmacology; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D016360:Clostridioides difficile / Q000187:drug effects; D047630:Depsipeptides; D005051:Eubacterium / Q000187:drug effects; D005243:Feces / Q000382:microbiology; D066298:In Vitro Techniques; D007422:Intestines / Q000382:microbiology; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010462:Peptostreptococcus / Q000187:drug effects; D011424:Propionibacterium / Q000187:drug effects; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D000081:Acetamides; D000900:Anti-Bacterial Agents; D047630:Depsipeptides; D023303:Oxazolidinones; D010456:Peptides, Cyclic; C041438:ramoplanin; D001414:Bacitracin; D017334:Teicoplanin; D014640:Vancomycin; D000069349:Linezolid